Leading Companies Enhancing Their Presence in the Orphan Drugs Service Market

The orphan drugs service market is gaining significant traction as the demand for treatments targeting rare diseases continues to rise. With advances in medical technology and supportive regulations, this market is set to experience substantial growth, unlocking new possibilities for personalized therapies. Below is a detailed overview of the market's size, key players, growth drivers, trends, and segmentation.

Projected Market Growth and Size of the Orphan Drugs Service Market by 2030
The orphan drugs service market is projected to expand rapidly and reach a valuation of $93.93 billion by 2030. This growth corresponds to a robust compound annual growth rate (CAGR) of 16.6% over the forecast period. Several factors are driving this surge, including the increasing need for personalized therapies targeting rare diseases, wider adoption of cutting-edge clinical trial technologies, expansion of orphan drug pipelines worldwide, enhanced use of real-world evidence, and ongoing regulatory backing for orphan drug development. Key trends expected to influence the market include a rising demand for specialized regulatory and development services, an emphasis on accelerated approval pathways, growing utilization of data-driven rare disease research platforms, expansion of patient-focused clinical development models, and stronger collaboration among stakeholders in the ecosystem.

Download a free sample of the orphan drugs service market sample:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28287&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Leading Players Dominating the Orphan Drugs Service Market
The orphan drugs service market features a range of prominent companies playing influential roles. Leading organizations include Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Novartis AG, AstraZeneca PLC, The Bristol-Myers Squibb Company, GSK plc., Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., IQVIA Inc., CSL Behring GmbH, Lonza Group AG, BioMarin Pharmaceutical Inc., Fortrea Holdings Inc., Medpace Inc., Sarepta Therapeutics, Caidya Inc., and Cevidra Inc. Notably, in April 2025, Netherlands-based pharmaceutical firm Norgine B.V. acquired Theravia Pharma, a France-based specialist in rare diseases and orphan drug services. This move aims to strengthen Norgine's growth path and broaden its rare disease therapy portfolio, positioning the company as a key partner in rare and specialty pharmaceuticals across Europe and the ANZ region.

Key Trends Supporting Growth in the Orphan Drugs Service Market
One important trend fueling market growth is the focus by major companies on securing regulatory approvals to accelerate the availability of rare disease treatments. Regulatory approvals provide official authorization from governmental bodies to legally manufacture, test, and market these therapies for patient use. For example, in February 2023, US-based gene therapy company Askbio GmbH received orphan drug designation from the European Commission for AB-1003, a novel investigational gene therapy targeting limb-girdle muscular dystrophy. This therapy is designed to restore FKRP enzyme activity through a single intravenous infusion. AB-1003 has also earned orphan drug designation from both the European Commission and the U.S. Food and Drug Administration, along with rare pediatric disease and fast track statuses from the FDA, underscoring the urgent unmet medical need. Currently, it is undergoing a Phase 1/2 clinical trial (LION-CS101) evaluating its safety and efficacy in adults with genetically confirmed limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9).

View the full orphan drugs service market report:
https://www.thebusinessresearchcompany.com/report/orphan-drugs-service-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Expanding Technological and Collaborative Developments in Orphan Drugs
Additionally, the orphan drugs service market is witnessing enhancements in clinical trial methodologies and patient-centric development strategies. Adoption of real-world evidence and data-driven research platforms is improving the precision and speed of rare disease therapy development. Collaboration between pharmaceutical companies, regulatory agencies, and patient groups is becoming more robust, enabling faster innovation and improved outcomes for underserved patient populations.

Segmentation Overview of the Orphan Drugs Service Market
This report segments the orphan drugs service market into several key categories for clearer insights:
1) By Type: Congenital Disease, Genetic Disease, Tumors and Cancer, Chronic, Other Types
2) By Therapeutic Area: Oncology, Metabolic Disorders, Neurological Disorders, Hematology, Infectious Diseases, Other Rare Diseases
3) By Application: Adult, Children

Further breakdowns include:
- Congenital Disease subtypes such as Heart Defects, Cleft Lip and Palate, Spina Bifida, Down Syndrome
- Genetic Disease subtypes including Cystic Fibrosis, Huntington Disease, Sickle Cell Anemia, Muscular Dystrophy
- Tumors and Cancer subcategories like Leukemia, Lymphoma, Neuroblastoma, Sarcoma
- Chronic disease divisions including Rare Metabolic, Rare Endocrine, Rare Cardiovascular, and Rare Neurological Disorders
- Other Types encompassing Rare Infectious, Immunological, Dermatological, and Ophthalmological Disorders

These detailed subcategories help pinpoint specific areas within the orphan drugs service market, guiding targeted development and investment strategies.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.